Comparative efficacy of HIV regimens
Highly-active antiretroviral therapy regimens that include non-nucleoside reverse transcriptase inhibitors were "modestly" better at virological suppression than protease inhibitor-based regimens, according to a direct meta-analysis of 12 trials conducted by the Oregon Evidence-based Practice Center. No difference was seen in death or disease progression or in withdrawal due to adverse events. However, the findings were complicated by an indirect analysis of 14 trials that included trials that were not head-to-head comparisons, which showed that NNRTI-based HAART was worse than PI-based regimens for virological suppression. The authors suggest that "indirect comparisons could be particularly unreliable for complex and rapidly evolving interventions such as HAART"...
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.